"I support uBiome's goal of providing their patients with the tools to monitor their family's microbiome over time and look forward to contributing to the Scientific Advisory Board." - Dr. Donovan, PhD, RD
SAN FRANCISCO (PRWEB) November 12, 2018
uBiome, the leader in microbial genomics, announces the addition of Dr. Sharon Donovan, PhD, RD, President of the International Society for Research on Human Milk and Lactation, Professor at the University of Illinois, and Melissa M. Noel Endowed Chair in Nutrition and Health, to its Scientific Advisory Board. Joining the board of leading scientists and doctors from around the world, Dr. Donovan will bring to uBiome her expertise on pediatric nutrition and neonatal intestinal development. The appointment will help uBiome continue its advancement in human microbiome research.
“Dr. Donovan’s research on neonatal intestinal development and intestinal disease provides valuable insight for understanding significant factors, such as nutrition, that may alter gut health,” Dr. Jessica Richman, PhD, co-founder and CEO of uBiome, said. “Her research aligns with uBiome’s passion for improving health outcomes, and we are honored to have her on our Scientific Advisory Board.”
A faculty member at the University of Illinois at Urbana-Champaign (UIUC) since 1991, Dr. Donovan’s laboratory conducts basic and translational research in the area of pediatric nutrition. From 1999 to 2009, she served as the Director of the Division of Nutrition at UIUC. She is active in her professional societies, having served as the President of the American Society for Nutrition from 2011 to 2012, and is currently serving as the President of the International Society Research on Human Milk and Lactation. Dr. Donovan also serves on National Academies committees, including the Food and Nutrition Board and she was elected to the National Academy of Medicine in 2017.Dr. Donovan has over 180 peer-reviewed publications and book chapters and receives grant support from the National Institutes of Health (NIH), the United States Department of Agriculture (USDA), and the food and pharmaceutical industry.
About joining uBiome's Scientific Advisory Board, Dr. Donovan said, "The pre and perinatal period are the most important times for establishing a healthy microbiota, which can have implications for lifelong health of the child. As a pediatric nutrition researcher who studies factors affecting the development of the infant microbiome, I support uBiome's goal of providing their patients with the tools to monitor their family's microbiome over time and look forward to contributing to the Scientific Advisory Board."
In addition to Dr. Donovan, the uBiome Scientific Advisory Board also includes Dr. Joseph DeRisi (MacArthur Genius and UCSF professor), Dr. Atul Butte (head of the Institute for Computational Health Sciences at UCSF), Dr. Katherine Pollard (Director, Gladstone Institute for Data Science and Biotechnology), Dr. Joel Palefsky (UCSF School of Medicine professor), Dr. George Church (leading geneticist at Harvard University), Dr. Liz Lipski (Academic Director of Nutrition and Integrative Health Programs at Maryland University of Integrative Health), Dr. Elaine Hsiao, PhD (UCLA), and other leading scientists. The company’s Medical Advisory Board includes Dr. Alan Green (Society for Participatory Medicine), Dr. Leo Treyzon (Cedars-Sinai Medical Center), Dr. Cynthia Geyer (Medical Director of Canyon Ranch, Lenox), Dr. Robynne Chutkan (Georgetown University Hospital), Michael Docktor (Boston Children’s Hospital), Dr. Tiffany Lester (Medical Director of Parsley Health in San Francisco), Dr. Joel Kahn (Founder of of the Kahn Center for Cardiac Longevity), as well as other accomplished clinicians.
Founded in 2012, uBiome is the leader in microbial genomics. The Company’s mission is to advance the science of the microbiome and make it useful to people. uBiome combines its patented proprietary precision sequencing™ with machine learning and artificial intelligence to develop wellness products, clinical tests, and therapeutic targets. uBiome has filed for over 250 patents on its technology, which includes sample preparation, computational analysis, molecular techniques, as well as diagnostic and therapeutic applications.
uBiome’s commercial products include SmartGut™, the world’s first sequencing-based clinical microbiome test, which identifies microbes in the gut for patients with chronic gut conditions such as IBD, IBS, Crohn’s Disease, and ulcerative colitis; SmartJane™, the first sequencing-based women’s health screening test, which genotypes all 19 clinically relevant strains of HPV, identifies four common STDs, and surveys more than 20 vaginal microbes associated with bacterial vaginosis and other conditions; and Explorer™, a health and wellness product to understand the role that food and lifestyle can play in wellness.
uBiome’s platform has been used by hundreds of thousands of consumers, patients, and doctors and more than 200 research institutions around the world, including the US Centers for Disease Control (CDC), US National Institutes of Health (NIH), Harvard University, Stanford University, the Massachusetts Institute of Technology (MIT), University of California, San Francisco, Oxford University, and the University of Sydney.
Since its launch, the company has received widespread recognition including CNN 10: Startups to Watch, the IVY Technology Award, CNN Future 30, and was named one of Fast Company’s Most Innovative Companies in Healthcare in 2016 and in Data Science in 2018, as well as a Technology Pioneer from the World Economic Forum in 2018. For more information, visit http://www.uBiome.com.